Top Drug Discovery Startups in 2027

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with [Amgen](endpts.com/amgen-lines-up-new-ai-biotech-partner-in-postera), [Pfizer](endpts.com/a-new-ai-startup-has-emerged-and-pfizer-likes-what-it-sees) and the [NIH](endpts.com/nih-grants-over-500m-to-create-antivirals-for-future-pandemics). PostEra also launched and led the world's largest open-science drug discovery effort; [COVID Moonshot](postera.ai/moonshot).

Biosimulation: Use computers to better understand the mechanisms of life. - Web-based simulation interfaces: Make your complex simulations easy to use. - Simulation data management: Organize the results of your simulations. - Custom hardware support: Make use of your hardware infrastructure to execute simulations. Big Data: Structure the information of life. - Clinical, pre-clinical and research data management: Organize your data from clinical, pre-clinical, or research studies. - Experimental data, protocol and workflow management: Use the latest tools to tie data to scientific workflows and digitized protocols. - Semantic data management: Use semantic technologies to enable higher order interpretation and analysis of your data. Visualization and data exploration: Gain insight through beautiful interfaces. - Rich web-based visualization dashboards: Use interactive visualizations of your data over the web. - Visualizing scientific data: Get the right perspective on your data.

Our mission is to harness advanced technologies to increase our understanding of the biology that underlies lifespan, and to seek interventions that enable people to lead longer and healthier lives. We bring together scientists and technologists, thinkers and tinkerers, to explore the fundamental biology of aging. At Calico, you'll work closely with scientists to help ask big scientific questions, and invent software to help answer them. We're part of the Alphabet family, which includes Google, Verily, Waymo, and other companies.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space. The Schrödinger platform is deployed by industry leaders worldwide for drug discovery, as well as for materials science in fields as diverse as aerospace, energy, semiconductors, oil and gas, automotive, and electronics displays. The platform also powers our own drug discovery efforts, from target identification to hit discovery to lead optimization. It also drives our research collaborations to develop novel medicines for critical public health needs. With more than 150 Ph.D. scientists on our team, we invest heavily in R&D. We’ve published over 400 peer-reviewed papers that demonstrate the strength of our physics-based approaches, and we’re continually pushing the limits of computer modeling.

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.